CDER’s Office of Compliance 2020 Annual Report - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. CDER's Office of Compliance 2020 Annual Report The Office of Compliance in FDA's Center for Drug Evaluation and Research released their 2020 annual report.  This report highlights the Office of Compliance's key initiatives in 2020 that had a direct impact on patient safety including their efforts to help address the COVID-19 pandemic. They took important actions to help increase access to critical medicines to treat patients with COVID-19, protect consumers from unsafe hand sanitizer products, protect patients from poorly compounded drugs, alert patients and health care professionals to nitrosamine-related recalls and shield patients from unproven products fraudulently claiming to prevent, treat or cure COVID-19.  Their accomplishments in 2020 demonstrate their unwavering commitment to shield patients from poor quality, unsafe and ineffective drugs. They look forward to continuing their mission in 2021. This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA